Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study

Abstract | Jun 13, 2024

Author

Aldoss I, et al.

Congress

European Hematology Association Annual Congress

Madrid, Spain | June 13 – 16, 2024